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Elevated gamma-glutamyl transferase is
associated with subclinical inflammation
independent of cardiometabolic risk factors
in an asymptomatic population: a
cross-sectional study
Shozab S. Ali1,2,3, Ebenezer T. Oni1,4, Michael J. Blaha5, Emir Veledar1, Hamid R. Feiz3, Theodore Feldman1,
Arthur S. Agatston1, Roger S. Blumenthal5, Raquel D. Conceicao6, Jose A. M. Carvalho6, Raul D. Santos6,7
and Khurram Nasir1,5,8,9*

Abstract
Background: Serum Gamma-Glutamyl Transferase (GGT), a marker of oxidative stress, has been suggested to be
independently associated with cardiovascular disease (CVD) events. We examined the association of serum GGT
levels with the burden of subclinical inflammation across a spectrum of metabolic conditions.
Methods: We evaluated 5,446 asymptomatic subjects (43 ± 10 years, 78 % males) who had an employer-sponsored
physical between 2008 and 2010. Highly sensitivity C-reactive protein (hsCRP) was measured as a marker of
underlying systemic inflammation. A linear regression of GGT quartiles with log transformed hsCRP and a
multivariate logistic regression of GGT quartiles with elevated hsCRP (≥3 mg/L) were performed.
Results: Median GGT was 31 IU/l (IQR: 22–45 IU/l), 1025 (19 %) had hsCRP ≥ 3 mg/L. The median hsCRP increased
with GGT quartiles (Q1: 0.9 mg/L, Q2: 1.1 mg/L, Q3: 1.4 mg/L, Q4: 1.6 mg/L, p < 0.001). Linear regression models
showed GGT in the fourth quartile was associated with 0.45 mg/L (95 % CI 0.35, 0.54, p < 0.001) increase in log
transformed hsCRP adjusting for risk factors. The Odds Ratio (OR) for an elevated hsCRP (≥3 mg/L) also increased
with higher GGT quartiles; GGT Q2 1.44 (95 % CI 1.12, 1.85), GGT Q3 1.89 (95 % CI 1.45, 2.46), GGT Q4 2.22 (95 % CI
1.67, 2.95), compared to GGT Q1. The strength of association increased in the presence of and combination of
metabolic conditions.
Conclusion: In our cohort of asymptomatic individuals a higher serum GGT level was independently associated
with increased burden of subclinical inflammation across metabolic states. These findings may explain GGT
association with increased CVD risk.
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Background
Gamma-Glutamyl Transferase (GGT) is an enzyme present
on the cell membranes of various tissues of the body; primarily the liver and also the kidneys, epididymis and lungs
[1–3]. It is responsible for the extracellular catabolism of
the antioxidant glutathione which leads to the production
of reactive oxygen species (ROS). ROS play key roles in the
inflammatory process and the progression of chronic diseases. Elevated GGT levels have been demonstrated to be
associated with cardiovascular disease (CVD) risk factors
including diabetes mellitus, hypertension, dyslipidemia and
the metabolic syndrome [3–7]. It has also been linked with
incident CVD [8, 9] and elevated levels have been found in
atherosclerotic plaques [10]. Although some studies have
demonstrated GGT as an independent marker of systemic
inflammation and oxidative stress [11], its association with
the CVD is still not clearly understood.
The highly sensitive C-reactive protein (hsCRP), an
established marker of inflammation, has been demonstrated to be a predictor of myocardial infarction, stroke,
peripheral arterial disease and sudden cardiac death
[12–14]. Earlier studies have suggested that both GGT
and hsCRP are associated with metabolic abnormalities
[1], however the extent of the association of GGT as a
marker for oxidative stress with hsCRP independent of
cardiometabolic risks has not been clearly defined. This
study examines the association of GGT distributed in
quartiles with hsCRP as a measure of the burden of subclinical inflammation across a spectrum of the metabolic
risk in a large asymptomatic cohort. We aim to assess
the association of GGT with subclinical inflammation
(hsCRP) and assess how this relationship is modified in
varying states of metabolic health.
Methods
Subjects

We evaluated a group of 5,446 asymptomatic men and
women, free of known cardiovascular disease, who submitted to routine clinical and laboratory health evaluation paid for by their employers from December 2008
to December 2010 at the Preventive Medicine Center of
the Hospital Israelita Albert Einstein in São Paulo,
Brazil. The examination protocol consisted of a clinical
consultation, laboratory evaluation, and ultrasonographic
abdominal scan. All individuals provided details of their
demographics, medical history, quantitative alcohol consumption, smoking status, and medication usage at the
time of their clinical consultation. Individuals with a
known history of liver diseases were not included in the
study.
Measurements

Information regarding medical history was obtained via
questionnaires. Physical activity level was assessed by a
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physical educator using the International Physical Activity
Questionnaire: Short Form (IPAQ-SF), which has been previously validated in a similar patient population [15, 16].
Smoking status was defined as current smoker versus
current non-smoker. Hypertension and dyslipidemia were
ascertained by a previous history of these conditions or the
use of blood pressure–lowering or lipid-lowering medications; those individuals with systolic blood pressure
>140 mmHg or diastolic blood pressure >90 mmHg at the
clinical evaluation were also labeled as having hypertension.
Diabetes mellitus was identified by previous physician diagnosis or by the use of a glucose-lowering medication. Obesity was defined as a body mass index (BMI) >30 kg/m2 or
>25 kg/m2 in individuals with a high waist circumference
(WC). WC was defined as high if >94 cm in men or
>80 cm in women. During physical examinations, blood
pressure was measured with an aneroid sphygmomanometer using the American Heart Association recommended
method [17]. WC was measured at the smallest diameter
between the iliac crest and the costal margin using a plastic
anthropometric tape held parallel to the floor. Alcohol consumption was quantified by the Alcohol Use Disorders
Identification Test (AUDIT) score [18]. The AUDIT score
was developed and validated by the World Health
Organization among men and women in different countries. We categorized a total AUDIT score of ≥8 as high alcohol consumption for men and ≥ 4 for women [19].
Hepatic steatosis was diagnosed after at least a 6-h fast
using an ACUSON XP-10 device (Mountain View, CA)
and was identified by the presence of an ultrasonographic
pattern of a bright liver, with evident contrast between hepatic and renal parenchyma, as previously described [20]. All
hepatic ultrasounds were read by board-certified radiologists. The metabolic syndrome was defined using criteria
from the American Heart Association/National Heart,
Lung, and Blood Institute scientific statement on the metabolic syndrome [21]. Patients with ≥3 of the following
metabolic risk factors were classified as having the metabolic syndrome: truncal obesity (≥102 cm [40 inches] for
men and ≥88 cm [36 inches] for women), high blood pressure (blood pressure ≥130/85 mmHg or the use of antihypertensive medications), hyperglycemia (fasting blood
glucose ≥100 mg/dL), low high-density lipoprotein cholesterol (HDL-C) (≤40 mg/dL for men and ≤50 mg/dL for
women), and hypertriglyceridemia (≥150 mg/dL) [21].
Blood specimens were collected after an overnight fast.
Plasma lipid, glucose, and liver transaminase levels (alanine aminotransferase [ALT] and aspartate aminotransferase [AST]) and Gamma-glutamyl transferase [GGT] levels
were measured by standardized automated laboratory
tests using a Vitros platform (Johnson & Johnson Clinical
Diagnostics, New Brunswick, New Jersey). High-sensitivity
CRP (hsCRP) levels were determined by immunonephelometry (Dade-Behring, GMbH, Mannhein, Germany). All
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Statistical analysis

triglyceride, HDL, SBP, fasting glucose, steatosis, LDL and
smoking, alcohol consumption, ALT and AST levels). The
association of GGT quartiles and hsCRP ≥3 mg/L in the
presence of metabolic syndrome (MS), hepatic steatosis
(HS) and across the combination of metabolic syndrome
and hepatic steatosis was evaluated in a logistic regression
analysis. All statistical analyses were performed using the
STATA statistical software, release 12.

The baseline characteristics of individuals across the GGT
quartiles were compared using the Pearson's χ2 test for
categorical variables and ANOVA test for continuous variables. As a result of the skewed distribution of ALT, AST,
and hsCRP, median values were compared using the nonparametric Kruskal-Wallis test. We log transformed
hsCRP and conducted a multivariate linear regression
analysis of lnhsCRP and GGT quartiles. We also evaluated
the relationship of elevated hsCRP (≥3 mg/L) with GGT
quartiles in a logistic regression model. An unadjusted
analysis was done first followed by sequentially adjusting
first for age and gender and then simultaneously adjusting
for other confounding factors (waist circumference,

Results
The study population consisted of 5,446 asymptomatic,
non-diabetic Brazilian subjects who were predominantly
male (78 %) with an average age of 43 ± 10 years. The distribution of GGT was: overall median 31 IU/l (IQR: 22–
45 IU/l) and cut off for the quartiles were; Q1: <22 IU/l,
Q2: 22–31 IU/l; Q3: 31–45 IU/l; Q4: >45 IU/l. The clinical, anthropometric and biochemical characteristics of
the study population across GGT quartiles are given in
Table 1. Individuals with GGT in the fourth quartiles had
the highest mean BMI, waist circumference, systolic and
diastolic blood pressures (p < 0.001). They also were more

tests were performed at the central laboratory of the Hospital Israelita Albert Einstein. This study was approved by
the local institutional review board of Hospital Israelita
Albert Einstein, and a waiver for informed consent was
obtained [22]. All data was de-identified for statistical
analysis.

Table 1 Baseline characteristics of study participants across GGT quartiles
Characteristics

GGT-Q1 (0–22 IU/L)

GGT-Q2 (22–31 IU/L)

GGT-Q3 (31–45 IU/L)

GGT-Q4 (>45 IU/L)

N = 1,465

N = 1,383

N = 1,254

N = 1,344

p-value

Male (%)

46

80

89

95

<0.001

Mean age, y (±SD)

41(9)

43(10)

45(10)

45(9)

<0.001

2

Mean BMI, kg/m (±SD)

24(3)

26(4)

27(4)

28(4)

<0.001

Mean waist circumference,
cm (±SD)

83(11)

90(11)

95(11)

98(10)

<0.001

Obesity, BMI ≥ 30 kg/m2 (%)

9

18

31

35

<0.001

Mean SBP, mmHg (±SD)

112(12)

118(12)

121(12)

124(13)

<0.001

Mean DBP, mmHg (±SD)

73(8)

76(7)

78(8)

80(8)

<0.001

HTN present(%)

6

11

15

19

<0.001

Antihypertensive (%)

6

10

14

19

<0.001

Median AST, IU/L (IQR)

25 (22,29)

28 (25,32)

30 (26,34)

34 (29,41)

<0.001

Median ALT, IU/L (IQR)

23 (19,29)

30 (25,38)

35 (29,45)

46 (35,61)

<0.001

Mean uric acid, mg/dl

4.8(1.3)

5.7(1.2)

6.2(1.2)

6.4(1.3)

<0.001

Median hsCRP, mg/L (IQR)

0.9 (0.5,1.8)

1.1 (0.6,2.1)

1.4 (0.7,2.7)

1.6 (0.9,2.9)

<0.001

Median triglycerides,
mg/dl (IQR)

88 (67,119)

107 (79,149)

130 (95,180)

151 (108, 211)

<0.001

Mean HDL, mg/dl (±SD)

54(14)

49(13)

45(12)

45(12)

<0.001

Mean LDL, mg/dl (±SD)

120(30)

131(32)

134(34)

138(34)

<0.001

Mean FBG, mg/dl (±SD)

85(8)

88(9)

91(10)

93(13)

<0.001

NAFLD present(%)

9

27

49

59

<0.001

Statin (%)

4

7

9

12

<0.001

Current smoker (%)

7

8

10

11

<0.001

High alcohol
consumption (%)

9

11

15

27

<0.001

Physically active (%)

80

79

73

70

<0.001
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likely to have higher levels of the other liver enzymes.
While the median (IQR) hsCRP for the entire population
was 1.2 (0.6, 2.4), it steadily increased with increasing
GGT quartiles. Figure 1 demonstrates that this steady increase across the GGT quartiles is independent of the
presence of MS, HS or obesity. Figure 2 shows the median
hsCRP levels across GGT quartiles in the presence of a
combination of hepatic steatosis, obesity and metabolic
syndrome. The median hsCRP steadily increased with
higher GGT quartiles as the number of metabolic conditions increased from none to three. A total of 1,008 (19 %)
individuals had hsCRP > 3 mg/L, 1,979 (36 %) had hepatic
steatosis, and 1,116 (21 %) had metabolic syndrome.

4
Median hsCRP Levels

3.5
3
2.5

Quartile 1

2

Quartile 2

1.5

Quartle 3

1

Quartile 4

0.5
0
With Metabolic Syndrome

Without Metabolic
Syndrome

Median hsCRP Levels

6
5
4
Quartile 1
Quartile 2

3

Quartle 3
2

Quartile 4

1
0
With Hepatic Steatosis

Without Hepatic Steatosis

5
4.5
Median hsCRP Levels

The adjusted linear regression analysis of the association between the GGT quartiles and log transformed hsCRP showed a steady increase in log
transformed hsCRP moving from the second to
fourth GGT quartiles, see Table 2. A logistics regression analysis, demonstrated that GGT levels in the
higher quartiles was associated with higher odds of
having elevated hsCRP (≥3 mg/L). The odds ratio
(OR) of an elevated hsCRP increased with higher
GGT quartiles from the second, third and fourth,
OR 1.44 (95 % CI 1.2, 1.85), 1.89 (95 % CI 1.45,
2.46) and 2.22 (95 % CI 1.67, 2.95) respectively,
compared to the first quartile, see Table 3. Table 4
shows the association between the higher GGT quartiles and elevated hsCRP across the spectrum of the
metabolic states. The presence of these metabolic
states is significantly associated with elevated hsCRP
across higher GGT quartiles, the effect is attenuated
with their absence.

4
3.5
3

Quartile 1

2.5

Quartile 2

2

Quartle 3

1.5

Quartile 4

1
0.5
0
With Obesity

Without Obesity

Fig. 1 Relationship of median hsCRP levels with GGT quartiles across
metabolic syndrome, hepatic steatosis and obesity. The median
hsCRP levels increase across the GGT quartiles independent of the
presence of metabolic syndrome, hepatic steatosis or obesity

Discussion
In this cross-sectional study of 5,446 healthy, nondiabetic Brazilian subjects, we found a significant relationship between GGT levels and hsCRP levels. Increasing GGT levels was associated with higher hsCRP
levels across the entire spectrum of metabolic risk factors. After adjusting for possible confounding factors,
the association persisted. Our findings suggest an
association between GGT and subclinical systemic
inflammation independent of cardiometabolic risk
factors. The elevation in hsCRP with increasing quartiles of GGT may be a pointer to the role of higher
GGT levels as a marker of cardiovascular risk [23].
This may help explain the association of increased
oxidative stress measured by GGT and future cardiovascular events [24, 25].
GGT plays a crucial role in the extracellular catabolism of the antioxidant glutathione [24, 26], which
facilitates the generation of ROS [12]. ROS have been
implicated in early atherosclerosis. It is postulated that
oxidative stress is the mediating factor of the association between GGT and cardiovascular disease [27].
However, it is unclear if GGT is induced as part of the
antioxidant response to oxidative stress from inflammation associated with CVD or if GGT is a contributor to oxidant stress in atherosclerosis by generating
ROS. Previous studies have demonstrated significant
cross-sectional independent associations between
serum GGT and CVD risk factors, like hypertension,
stroke, and type 2 diabetes [3, 7, 23, 27, 28]. Liu et al.
demonstrated the association of GGT and cardiometabolic risk factors was present both in a cross-sectional
and in a prospective study of young healthy men [29].
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5
4.5
4

Median hsCRP Levels

3.5
3
Quartile 1
2.5

Quartile 2
Quartle 3

2

Quartile 4
1.5
1
0.5
0
None

At least one of HS, MS Combination of any
or obesity
two

All three present

Fig. 2 Median hsCRP levels in GGT quartiles across a combination of metabolic conditions; hepatic steatosis (HS), metabolic syndrome (MS) and
obesity. The median hsCRP steadily increases with higher GGT quartiles as the number of metabolic conditions increases from none to three

Our findings indicate the association between GGT
and hsCRP, an established marker for subclinical CVD,
is independent of the metabolic conditions. This finding is supported by previous studies. Abdou et al.
established an association between GGT and elevated
levels of inflammatory biomarkers [15]. In another
study, Bozbas et al., in a study of 232 patients (Mean
age: 60 ± 10 years, 71 % females), demonstrated a significant correlation between GGT levels and CRP (r =
0.20, p = 0.003) mostly among individuals with metabolic syndrome [16]. In our study each of the metabolic conditions - metabolic syndrome, obesity or
hepatic steatosis were associated with hsCRP; a combination of all these metabolic conditions was still associated with higher GGT quartiles.
This study demonstrated that the association between GGT and hsCRP presented a dose-response association. Lee et al., from the Coronary Artery Risk

Table 2 Linear regression analysis of GGT quartiles and lnhsCRP

Development in Young Adults (CARDIA) study,
showed a similar association. From their study, serum
GGT predicted future concentrations of hsCRP in a
dose–response manner [30]. In another large study
from a representative sample of the US population
using the third National Health and Nutrition Examination Survey (NHANES III), Lee et al. also demonstrated the association between serum GGT and CRP
concentration across ethnic subgroups. They reported
a strong association among all ethnic subgroups irrespective of the metabolic syndrome status [12], this
further supports our findings. We have demonstrated
for the first time that increasing GGT levels is associated with hsCRP independent of the metabolic states.
We must mention, that there have been some controversies regarding this association. In a recent study
from the Prevention of Renal and Vascular End-stage

Table 3 Odds ratio of elevated hsCRP (≥3 mg/L) with GGT
quartiles from a logistic regression analysis

Model 1

Model 2

Model 3

Model 1

Model 2

Model 3

Quartile 1 (ref)

1.0

1.0

1.0

Quartile 1 (ref)

1.0

1.0

1.0

Quartile 2

0.19 (0.11,0.26),
p < 0.01

0.32 (0.24,0.39),
p < 0.01

0.18 (0.10,0.27),
p < 0.001

Quartile 2

1.25 (1.02,1.54),
p = 0.036

1.82 (1.45,2.27),
p < 0.001

1.44 (1.12,1.85),
p = 0.004

Quartile 3

0.45 (0.37,0.53),
p < 0.001

0.61 (0.53,0.69),
p < 0.001

0.32 (0.23,0.04),
p < 0.001

Quartile 3

1.74 (1.42,2.13),
p < 0.001

2.86 (2.28,3.60),
p < 0.001

1.89 (1.45,2.46),
p < 0.001

Quartile 4

0.59 (0.52,0.67),
p < 0.001

0.77 (0.69,0.85),
p < 0.001

0.45 (0.35,0.54),
p < 0.001

Quartile 4

1.97 (1.62,2.40),
p < 0.001

3.48 (2.76,4.39),
p < 0.001

2.22 (1.67,2.95),
p < 0.001

Model 1: unadjusted
Model 2: adjusted for age and gender
Model 3: model 2 + SBP, hdl-c, triglyceride-c, ldl-c, fasting glucose, waist
circumference, physical activity, alcohol, AST, ALT, smoking, steatosis, statins

Model 1: unadjusted
Model 2: adjusted for age and gender
Model 3: model 2 + SBP, hdl-c, triglyceride-c, ldl-c, fasting glucose, waist
circumference, physical activity, alcohol, AST, ALT, smoking, steatosis, statins
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Table 4 The logistic regression of the presence of hsCRP >3 mg/L and GGT quartiles across a combination of metabolic syndrome
and hepatic steatosis
None N = 81

HS only N = 1,979

MS only N = 1,116

HS and MS N = 2,270

Quartile 1 (ref)

1.0

1.0

1.0

1.0

Quartile 2

1.64 (1.25, 2.15) p < 0.001

2.13 (1.07, 4.26) p = 0.03

1.19 (0.42, 3.38) p = 0.749

2.94 (1.05, 8.20) p = 0.04

Quartile 3

2.14 (1.56, 2.92) p < 0.001

3.34 (1.69, 6.62) p = 0.001

1.50 (0.54, 4.20) p = 0.440

3.88 (1.42, 10.60) p = 0.008

Quartile 4

2.43 (1.69, 3.50) p < 0.001

4.12 (2.07, 8.21) p < 0.001

1.72 (0.61, 4.86) p = 0.303

3.98 (1.45, 10.94) p = 0.007

Model was adjusted for age, gender, AST, ALT, statins, smoking

Disease (PREVEND) study, the association of circulating GGT with CVD risk had comparable strength to
risk of established cardiovascular risk factors [31].
While GGT showed a positive association with stroke
risk in the model adjusted for traditional risk factors
including CRP, the association with coronary heart
disease (CHD) risk was abrogated when CRP was included in their model. The authors argued that elevated GGT levels could reflect chronic subclinical
inflammation, often characterized by elevated CRP
levels. As such CRP may be a confounder in the association between GGT and CVD [31]. Although the authors did not find the potential utility of GGT in CVD
risk assessment, they support the argument that it
plays a role in the etiology of CVD and potential
causal relevance to CVD is important [31].
It is relevant to note that elevated levels of GGT in
asymptomatic individuals can be due to many factors
including but not limited to dyslipidemia, smoking, alcohol consumption, hypertension, hyperglycemia and,
oral contraceptive use in women [32, 33]. Individuals
with elevated GGT levels encountered in clinical practice with no liver dysfunction can be evaluated further
for presence of subclinical inflammation. These individuals can be worked up for the presence of early atherosclerosis and may be considered candidates for more
aggressive preventive strategies. This, however, needs to
be studied further in future prospective cohort studies.
There are however some limitations to this study.
Firstly, it is a cross-sectional study and as such causal relationships cannot be determined. Secondly, the study
was performed in a cohort of Brazilian subjects which
may limit the generalization. Also, the medical history
was obtained from the subjects via questionnaire which
is a potential source of recall bias. The use of ultrasound
for diagnosing hepatic steatosis is limited by low sensitivity especially in obese individuals, and its inability to
evaluate hepatic fibrosis. Another possible limitation is
the “healthy worker effect” in the employee population.
The strength of this study lies in its large population
size including participants of both genders, each
undergoing extensive cardiovascular risk assessment.
This allowed for adjustment for potentially confounding risk factors. Finally, our use of asymptomatic

subjects may help make this data more relevant, as
hsCRP measurement is performed commonly as part
of a primary prevention strategy.

Conclusion
In conclusion, this study demonstrates an association
between GGT and elevated hsCRP levels among
asymptomatic individuals, independent of obesity,
metabolic syndrome and other cardiovascular risk factors. Additional research is however needed to elucidate the relationship between GGT and systemic
inflammation as a measure for accurate prediction of
future cardiovascular disease and the potential impact
of risk reduction with therapies that lower GGT.
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